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Research
Although several international studies have
shown the effects of arsenic on elevated lung
cancer risk, there has been relatively little
research on its role in nonmalignant respira-
tory illnesses (Chiou et al. 1995; Mazumder
et al. 1998; Smith et al. 1998). Studies from
India (Mazumder et al. 1998), Bangladesh
(Milton et al. 2003; Milton and Rahman
2002), and Chile (Smith et al. 1998) have
reported a high prevalence of respiratory symp-
toms among As-exposed individuals; these
studies were largely limited to people exposed
to high As concentrations who had visible
arsenical skin lesions. Six studies from India
and Bangladesh showed a high prevalence of
respiratory symptoms among people exposed
to water As concentrations > 500 µg/L and
with visible arsenical lesions (De et al. 2004;
Mazumder et al. 2000, 2005; Milton et al.
2003; Milton and Rahman 2002; von
Ehrenstein et al. 2005); three of these studies
were conducted in the same source population
in India (Mazumder et al. 2000, 2005; von
Ehrenstein et al. 2005). The first study
(Mazumder et al. 2000), which had a large
sample size (n = 6,864), reported 5–23 times
higher prevalence of common respiratory
symptoms (e.g., chronic cough, abnormal
chest sound, shortness of breath) among peo-
ple with arsenical skin lesions. The second
study (von Ehrenstein et al. 2005), with a
smaller sample size (n = 287), reported a
higher risk [odds ratios (ORs), 2.8–3.8] of
common respiratory symptoms and lower
FEV1 (forced expiratory volume measured in
1 sec) and FVC (forced vital capacity) among
people with arsenical lesions. In their most
recent study (n = 258), Mazumder et al.
(2005) reported a 10-fold increased risk of
chronic obstructive pulmonary disease
(COPD) among people with arsenical skin
lesions. In an earlier study from India in
156 As-exposed (> 600 µg/L) individuals with
skin lesions, De et al. (2004) reported that
57% of subjects had respiratory symptoms and
53% had restrictive lung disease. The authors
also found that 41% of the study participants
had both obstructive and restrictive lung
diseases. Two studies from neighboring
Bangladesh have also reported an elevated risk
of respiratory symptoms such as chronic cough
[risk ratio (RR) = 2.1] and chronic bronchitis
(RR = 2.68) associated with As exposure in
people with visible skin lesions (Milton et al.
2003; Milton and Rahman 2002).
In a study in an As-endemic area of Chile,
Smith et al. (2006) found a high mortality
from COPD due to arsenic. Two other stud-
ies from Chile also reported a high prevalence
of respiratory illness among children with
arsenical skin lesions compared with those
without such lesions (Zaldivar 1980; Zaldivar
and Ghani 1980). In addition, in an interven-
tion study, Borgono et al. (1977) observed a
reduction in prevalence (from 23% to 7%) of
common respiratory illnesses after providing
As-free water, reinforcing the effect of As on
chronic respiratory illness. 
In almost all of the studies published to
date, assessments of respiratory illnesses are
problematic for two reasons. First, most of
these studies were conducted among people
with visible arsenical lesions that may have
biased the assessment of respiratory symptoms
in the study participants (Mazumder et al.
2000). Second, respiratory symptoms were
assessed either by self-report, which may be
affected by recall bias, or by lung function
tests, which require patient cooperation and
may be subject to information bias, leading to
either over- or underestimation of the true
measure of association. For instance, if persons
with skin lesions or high As exposure are more
cooperative or if they receive more attention,
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BACKGROUND: Arsenic from drinking water has been associated with malignant and nonmalignant
respiratory illnesses. The association with nonmalignant respiratory illnesses has not been well
established because the assessments of respiratory symptoms may be inﬂuenced by recall bias or
interviewer bias because participants had visible skin lesions.
OBJECTIVES: We examined the relationship of the serum level of Clara cell protein CC16—a novel
biomarker for respiratory illnesses—with well As, total urinary As, and urinary As methylation
indices.
METHODS: We conducted a cross-sectional study in nonsmoking individuals (n = 241) selected from
a large cohort with a wide range of As exposure (0.1–761 µg/L) from drinking water in Bangladesh.
Total urinary As, urinary As metabolites, and serum CC16 were measured in urine and serum
samples collected at baseline of the parent cohort study.
RESULTS: We observed an inverse association between urinary As and serum CC16 among persons
with skin lesions (β = –0.13, p = 0.01). We also observed a positive association between secondary
methylation index in urinary As and CC16 levels (β = 0.12, p = 0.05) in the overall study popula-
tion; the association was stronger among people without skin lesions (β = 0.18, p = 0.04), indicat-
ing that increased methylation capability may be protective against As-induced respiratory damage.
In a subsample of study participants undergoing spirometric measures (n = 31), we observed inverse
associations between urinary As and predictive FEV1 (forced expiratory volume measured in 1 sec)
(r = –0.37; FEV1/forced vital capacity ratio and primary methylation index (r = –0.42, p = 0.01).
CONCLUSIONS: The ﬁndings suggest that serum CC16 may be a useful biomarker of epithelial lung
damage in individuals with arsenical skin lesions. Also, we observed the deleterious respiratory
effects of As exposure at concentrations lower than reported in earlier studies. 
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via http://dx.doi.org/ [Online 6 November 2007]the measure of association would be, to some
extent, overestimated. However, detection of
respiratory illness can be improved and bias
can be avoided by using valid biomarkers. In
the present study, we examined the serum
level of Clara cell protein CC16, a novel bio-
marker for detecting respiratory illnesses, in
241 nonsmokers chronically exposed to wide
levels of As from drinking water. Although the
clinical signiﬁcance of early epithelial changes
detected by serum CC16 remains to be fully
determined, several studies have shown that
CC16 can be used as a biomarker for detecting
respiratory effects induced by environmental
exposures such as air pollution and tobacco
smoking (Bernard et al. 1994; Berthoin et al.
2004; Broeckaert and Bernard 2000;
Broeckaert et al. 2000; Johansson et al. 2005;
Lagerkvist et al. 2004). The objective of our
analyses was to examine the effects of As expo-
sure on lung injury using the serum level of
CC16 and several indices of As exposure. 
Methods
Selection of study participants. The data we
present here are from a subset of participants of
a large ongoing prospective cohort study in
Araihazar, Bangladesh. The goals of the parent
multidisciplinary epidemiologic investigation
are to examine the health effects of As exposure
from drinking water in order to guide policy. A
detailed description of the parent cohort study
has been published elsewhere (Ahsan et al.
2006a). In short, 11,746 adults who had been
drinking As-contaminated water at a broad
range of As concentrations for at least 3 years
were recruited between October 2000 and
May 2002 and have since been followed at
2-year intervals. Demographic and smoking
data and water, urine, and blood samples were
collected at the baseline and at follow-up visits.
At each visit, As-induced skin lesion status was
evaluated, quantified, and validated by our
study physicians and expert dermatologists
(Ahsan et al. 2006a). As-related skin lesions are
known to be a hallmark of chronic As poison-
ing. These lesions include discoloration of skin
with pigmentation and, in many cases, are
accompanied by thickening of the skin of
palm, sole, torso, and upper limbs (Ahsan et al.
2006b; Mazumder et al. 1998). We instituted
a structural protocol by adapting the methods
for quantitative assessment of body surface in
burn patients. Details of the clinical examina-
tion protocol for skin-lesion assessment were
previously described (Ahsan et al. 2006b).
At baseline, the study physicians, who were
blind to information on the As level in partici-
pants’ drinking wells, identiﬁed 714 individu-
als with arsenical skin lesions. A total of
594 cases of skin lesions and a random sample
of 1,041 individuals without skin lesions were
selected for a study of urinary As metabolites
and genetic susceptibility (Ahsan et al. 2007).
For the present study, we selected a random
sample of 130 cases and 130 noncases from the
156 cases and 422 noncases who were never-
smokers, had data on urinary total As and As
metabolites, and had blood samples available.
After discarding samples that did not have
enough serum for the CC16 assay, we included
241 individuals (128 cases and 113 noncases)
in the analyses. The project was approved by
the Columbia University Institutional Review
Board and the Bangladesh Medical Research
Council. Verbal informed consent was
obtained from all the participants for this study
before they were enrolled into the study.
Sample collection, storage, and processing.
Water sample collection and As assay. Water
samples from the wells the study participants
regularly drank from were collected in 50-mL
acid-washed tubes following pumping the
well for 5 min. These samples were analyzed
for As concentration by graphite furnace
atomic-absorption (GFAA) with a Hitachi
Z-8200 system (Hitachi, Tokyo, Japan) in
the Geochemistry Laboratory at Lamont
Doherty Earth Observatory of Columbia
University. A detailed description of the
water-collection procedure has been reported
elsewhere (van Geen et al. 2002).
Urine sample collection and As assay.
Spot urine samples were collected in 50-mL
acid-washed tubes and kept in portable cool-
ers with ice packs (carried by the research
team) until storage at –20°C at the end of the
day. All samples were frozen until shipment
on dry ice to Columbia University. Urinary
As concentration assays were performed with
GFAA using a Perkin-Elmer Analyst 600
graphite furnace system (PerkinElmer,
Wellesley, MA, USA) in the Department of
Environmental Health Sciences of Columbia
University, as described by Nixon et al.
(1991). Levels of As in urine were expressed
as micrograms of As per gram creatinine, and
creatinine levels were analyzed by a colorimet-
ric Sigma Diagnostics Kit (Sigma Chemical
Co., St. Louis, MO, USA).
Urinary As metabolites assay. Urinary As
metabolites were assayed by inductively cou-
pled plasma-mass spectrometry with dynamic
reaction cell (ICP-MS-DRC) coupled to high-
performance liquid chromatography (HPLC).
ICP-MS-DRC was used as a detector for As
metabolites chromatographically separated on
an Anion Exchange Column (Hamilton
PRP-X100; Hamilton, Reno, NV, USA) with
10 mM ammonium nitrate/ammonium phos-
phate, pH 9.1, as mobile phase (van Geen
et al. 2002). The excellent separation power of
HPLC coupled with very low detection limits
of ICP-MS-DRC allowed us to detect arseno-
choline (AsC), arsenobetaine (AsB), inorganic
As (InAs; i.e., AsIII, AsV), total monomethyl-
arsonic acid (MMA), and total dimethylarsinic
acid (DMA).
Blood sample collection and processing.
Blood samples were collected in 10-mL vacu-
tainers with silica clot activator and polymer
gel separator. Blood samples were stored in a
cold box at 4°C immediately after collection.
To separate serum from the whole blood, the
blood samples were centrifuged 10 min at
4,000 rpm. Separated samples were then
stored at –20°C until they were shipped on
dry ice to Columbia University for analysis.
The serum samples were aliquotted into small
plastic tubes and shipped on dry ice to the
laboratory at the Catholic University of
Louvain for analysis of CC16. 
CC16 assay. The concentration of CC16
in serum was determined using the assay
method described by Hermans et al. (2001).
This assay uses the rabbit anti-protein 1 anti-
body from Dakopatts (Glostrup, Denmark)
and the CC16 protein puriﬁed in the labora-
tory as a standard. To avoid interferences by
complement, rheumatoid factor, or chylo-
microns, sera were prepared by heating at
56oC for 30 min and by adding polyethylene
glycol (16% vol/vol, 1/1) and trichloroacetic
acid (10% vol/vol, 1/40). After overnight pre-
cipitation at 4°C, the serum samples were cen-
trifuged (at 3,000 × g for 10 min) and CC16
was determined in the supernatants. This assay
has a detection limit of 0.5 µg/L and an aver-
age analytical recovery of 95%. All laboratory
assays for serum CC16 were performed in
duplicate at two different and independent
dilutions of the samples to achieve maximum
accuracy. The within- and between-run coefﬁ-
cient of variation (CV) was between 5 and
10%, and the values were in the normal range
(5–20 µg/L for healthy subjects 20–60 years of
age) (Shijubo et al. 1999a, 1999b). In epi-
demiologic studies of biomarkers, CVs up to
15% are often acceptable (Tworoger and
Hankinson 2006). The CC16 concentration
in serum is in good agreement with levels
obtained with a monoclonal antibody–based
enzyme-linked immunosorbent assay (ELISA)
kit recently developed by Pharmacia (Human
Clara Cell Protein ELISA; Pharmacia
Biotechnology, Uppsala, Sweden). 
Indices of As exposure and metabolism.
Cumulative As exposure index. At the base-
line interview for each participant, informa-
tion on daily water consumption and duration
of well use was collected for wells used on a
regular basis. In addition, similar information
was also collected on any other well that a par-
ticipant used currently (or had used in the
past). When the previously used well was
within the study area and the As concentration
was known, As concentration of the previous
well was incorporated in the calculation of the
cumulative As exposure index (CAI). Based on
well utilization history, we calculated the CAI,
which is the sum of the products of the
amount of water consumed per day (liters per
Arsenic, CC16, and respiratory effects
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grams per liter) × the duration of well use
(days) for each well (Ahsan et al. 2006b). The
CAI is a good indicator of long-term As expo-
sure (Ahsan et al. 2006a).
Arsenic metabolism indices. The percent-
ages of InAs, MMA, and DMA were calculated
after subtracting AsC and AsB (i.e., nontoxic
dietary sources of As) from the total. An alter-
native method for describing As metabolite
data employs primary (PMI) and secondary
(SMI) methylation indices. PMI is the ratio of
MMA to InAs, and SMI is the ratio of DMA
to MMA.
Lung function test using spirometry. From
the 241 study subjects, we chose a random
sample of 40 individuals without skin lesions
for lung function testing using spirometry.
The tests were repeated at least 3 times to
obtain acceptable maneuvers. After accounting
for individuals who were unavailable for test-
ing (n = 4) or who produced readings of poor
quality (n = 5), a total of 31 spirometry test
results were available for analysis. We used a
portable, battery-operated ultrasound transit-
time based spirometer (EasyOne; NDD
Medical Technologies, Chelmsford MA, USA;
and Zurich, Switzerland) for pulmonary func-
tion tests. The device is standardized to meet
American Thoracic Society guidelines for lung
function tests. The EasyOne has been used in a
number of research studies in different coun-
tries and at a number of teaching hospitals in
the United States (Menezes et al. 2005; NDD
Medical Technologies 2007; Perez-Pedilla
et al. 2006). Although, the EasyOne does not
require calibration, we compared its readings
among a number of patients and healthy vol-
unteers with readings from a standard spirome-
ter clinically used at the Dhaka Chest Institute
in Bangladesh, in collaboration with M.
Rashidul Hasan, an expert pulmunologist.
Agreement between the spirometry used at the
hospital and EasyOne was excellent.
Statistical analysis. Preliminary analysis
involved calculations of frequency distribu-
tions, means, and tabular statistics. We per-
formed Student’s t-tests for continuous
variables between two different groups (e.g.,
with and without visible skin lesions, lung
function tests). The distributions of the out-
come and As variables were skewed; therefore,
they were log-transformed. Pearson correlation
coefﬁcients were used to evaluate the relation-
ship between CC16 and As exposure variables,
as well as the relationships of lung function
indices with urinary As and As methylation
indices. Multivariate linear regression was used
to evaluate the associations of As exposure
variables and urinary As methylation indices
with log-transformed CC16 in all the partici-
pants, and was performed separately by skin
lesion status. Potential confounders including
age, sex, and body mass index (BMI) were
included in the multiple linear regression
models. A conventional cutpoint (70% of the
predictive value) (De et al. 2004) was selected
to indicate low and high status of lung func-
tion in the subgroup with spirometry data.
We conducted t-tests to compare levels of uri-
nary As and serum levels of CC16 in partici-
pants with low and high lung function. In
these analyses, all statistical tests were two-tail
tests based on the type I error rate of 0.05.
Study participants with missing information
on any of the covariates were excluded from
regression analyses (n = 22). All statistical
analyses were conducted using the SAS 8.2
statistical package for Windows (SAS Institute
Inc., Cary, NC, USA).
Results
The average age of the study participants was
37 years (Table 1). Cases with skin lesions
were about 6 years older than noncases.
Because of our study design, roughly one-half
(53%) of the study participants had arsenical
skin lesions. Among individuals with skin
lesions, 34.3% of male and 35.1% of female
participants consumed water containing
> 50 µg/L As. The average BMI among the
study participants was 20; people with skin
lesions had slightly lower BMIs (mean ± SD,
19.4 ± 2.6) than those without lesions
(20.4 ± 3.3). As in the overall cohort (Ahsan
et al. 2006b), cases with skin lesions had
lower body weight than noncases. 
The mean As concentration in drinking
water was 134 µg/L (Table 1). Individuals with
skin lesions consumed water with a signifi-
cantly higher As concentration (159 µg/L)
than those without lesions (105 µg/L). A larger
proportion of individuals with skin lesions
(37%) than without (25.7%) were also found
to drink water > 50 µg/L As concentration.
Individuals with skin lesions had signiﬁcantly
higher urinary As (461 µg/g creatinine) than
those without (264 µg/g creatinine). Also, the
CAI was higher in people with skin lesion
(1,815 mg) than in those with no lesions
(1,134 mg). The primary As methylation index
(MMA/InAs) was also significantly higher
among arsenical skin lesion cases (1.01) than
noncases (0.84) (p < 0.01). Conversely, the sec-
ondary methylation index (DMA/MMA) was
lower among people with skin lesions (5.6)
than among those without (7.8).
Serum CC16 levels were inversely related
to urinary As concentrations (r = –0.11,
p = 0.07), although the association did not
reach statistical signiﬁcance at p < 0.05 among
all individuals. However, among individuals
with arsenical lesions, we found significant
associations of urinary As (r = –0.24, p = 0.01)
and CAI (r = –0.17, p = 0.05) with CC16
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Table 2. Linear regression analyses for the effects of different measures of As exposure on serum CC16 levels among all participants, as well as stratiﬁed by skin
lesion status.
Log-transformed CC16
Overall model Subjects with skin lesions Subjects without skin lesions
Log-transformed (n = 238) (n = 126) (n = 112)
measure Parameter estimatesa p-Value Parameter estimatesa p-Value Parameter estimatesa p-Value
Water As (µg/L)  –0.01841 0.31 –0.03853 0.15 0.00564 0.82
Urinary creatinine-adjusted As (µg/g creatinine)  –0.06070 0.10 –0.13462 0.01 0.03476 0.54
Cumulative As (mg)  –0.01745 0.29 –0.04527 0.06 0.01547 0.52
aParameter estimates were adjusted for age, sex, and BMI. 
Table 1. Demographic, CC16, and As-related variables for the study participants, by skin lesion status.
Subjects with Subjects without
Overall skin lesions skin lesions
(n = 241) (n = 128) (n = 113) p-Valuea
Male (%) 32.3 50.0 12.0 < 0.01
CC16 (µg/L) 6.39 ± 3.1 6.42 ± 3.3 6.36 ± 2.9 0.87
Age (years) 37 ± 9.5 39.7 ± 9.8 33.8 ± 8.1 < 0.01
BMI 19.9 ± 3.0 19.4 ± 2.6 20.4 ± 3.3 0.01
Water As (µg/L) 134 ± 153.8 159 ± 181.1 105 ± 109.2 < 0.01
Urinary As (µg/L) 189 ± 250.2 213 ± 251.3 162 ± 182.3 0.10
Creatine (µg/L) 57 ± 45.8 51 ± 41.5 64 ± 49.6 0.03
Urinary creatinine-adjusted As 368 ± 367.6 461 ± 451.4 264 ± 194.5 < 0.01
(µg/g creatinine)
Cumulative As (mg) 1,499 ± 2,436 1,815 ± 2,763 1,134 ± 1,941 0.02
MMA/InAs 0.932 ± 0.5 1.01 ± 0.48 0.84 ± 0.52 0.01
DMA/MMA 6.6 ± 3.0 5.6 ± 2.6 7.8 ± 4.6 < 0.01
Values shown are mean ± SD except where indicated. 
ap-Value from t-test or chi-squared tests.levels. The association between water As
and CC16 was not statistically significant
(r = –0.12, p = 0.15).
Multiple linear regression analyses also
revealed no significant association between
urinary As and log-transformed CC16 values
(β = –0.06, p = 0.10) adjusting for age, sex,
and BMI in the overall study population
(Table 2). Among individuals with skin
lesions, we found a signiﬁcant association of
CC16 with urinary As (β = –0.13, p = 0.01)
and a marginally significant association of
CC16 with CAI (β = –0.04, p = 0.06).
This analysis revealed a weak negative asso-
ciation between CC16 and the MMA/InAs
ratio (β = –0.08, p = 0.18) but a marginally
significant positive association with the
DMA/MMA ratio (β = 0.12, p = 0.05)
(Table 3). Among individuals without arseni-
cal lesions, the association between CC16 and
DMA/MMA ratio was even stronger (β = 0.18,
p = 0.04), suggesting that As metabolism may
be protective of respiratory injury. In addition,
our overall data showed a signiﬁcant associa-
tion of serum CC16 with MMA% (β = –0.16,
p = 0.03) but not with DMA% (β = 0.33,
p = 0.16) in linear regression models after
adjusting for age, sex, and BMI.
We also conducted lung function tests by
using a spirometer in a small sample (n = 31)
to ascertain the association between CC16 and
clinical lung function. We observed strong
inverse associations between urinary As
and predictive FEV1 (r = –0.37, p = 0.03;
β = –0.017, p = 0.03), FVC (r = –0.35,
p = 0.04; β = –0.014, p = 0.04) and FEV1/
FVC ratio (r = –0.36, p = 0.04; β = –0.009,
p = 0.04) among this subset of the study popu-
lation. Our data show a strong inverse associa-
tion between FEV1/FVC and PMI (r = –0.42,
p < 0.01) (Table 4). Further, we found that
individuals (23%) with low (≤ 70) predictive
FEV1 and FVC values also had marginally sig-
nificantly lower CC16 compared with those
with higher values (> 70; 3.58 and 7.71 µg/L,
p = 0.05), confirming that individuals with
chronic respiratory illness have low levels of
serum CC16 (Table 5).
Discussion
To our knowledge, this is the first study to
systematically assess the effects of As from
drinking water on respiratory illness using
biomarkers of As exposure and lung injury.
We found an inverse association between uri-
nary As and serum CC16 level among cases
with skin lesions. This could be because indi-
viduals with skin lesions are either exposed to
a higher levels of As or they are more suscepti-
ble to other health effects (especially respira-
tory effects) of As exposure. The significant
associations between serum CC16 and
FEV1/FVC reinforce the fact that serum
CC16 is a biomarker of lung function, and it
may be useful in assessing early respiratory
damage induced by As, especially among indi-
viduals with skin lesions.
Our analyses also showed positive associa-
tions of CC16 levels with secondary As
methylation index (MMA/DMA), particu-
larly among individuals without skin lesions,
suggesting that those with better methylation
capacity are less prone to respiratory effects of
As. The inverse association of CC16 with
MMA% also suggests that individuals with
incomplete methylation are more susceptible
to the respiratory effect of As. In a large case–
control study of As-related skin lesions within
the parent cohort study, we also found a
dose–response relationship between risk of
skin lesions and %MMA (Ahsan et al. 2007).
Although the mechanism of As-induced
nonmalignant respiratory illness is not
known, several studies have shown that a
large amount of As is deposited and stored in
the lung, especially in the epithelium
(Gerhardsson et al. 1988; Rosenberg 1974;
Saady et al. 1989). It is possible that the
deposited As in the lung acts like some other
metals by enhancing tissue inflammation or
increasing pulmonary fibrosis, leading to
impaired respiratory function (Nemery 1990).
Hotta (1989) suggested that chronic As poi-
soning renders the respiratory tract more sus-
ceptible to infection. von Ehrenstein et al.
(2005) suggested that decreased lung function
due to As exposure may induce fibrosis and
lung impairment. De et al. (2004) suggested
an inﬂammation-mediated immunologic basis
of arsenic toxicity in the lung. Some recent
articles also suggested a role of oxidative stress
in As-induced lung toxicity (Hays et al. 2006;
Lantz and Hays 2006).
CC16 is one of the 20 proteins secreted by
Clara cells in the lung’s alveolar epithelium,
and it plays a major role in protecting the alve-
olar epithelium from pollutants (Broeckaert
et al. 2000). CC16 reﬂects early lung damage
due to chronic environmental exposures
(Bernard et al. 1994, 2005; Berthoin et al.
2004; Broeckaert et al. 2000; Gioldassi et al.
2004; Johansson et al. 2005; Lagerkvist et al.
2004; Shijubo et al. 1999a, 1999b). In either
chronic inﬂammation or ﬁbrosis of the lung,
alveolar Clara cells are damaged, resulting in a
reduced CC16 concentration over time.
Recent studies in adults and children have
shown significantly lower levels of CC16 in
individuals with asthma and rhinitis compared
with healthy individuals (Gioldassi et al. 2004;
Johansson et al. 2005; Shijubo et al. 1999a,
1999b). Serum CC16 has also been shown to
be a reliable measure of lung function in work-
ers exposed to crystalline silica or foundry dust
(Bernard et al. 1994; Berthoin et al. 2004;
Broeckaert et al. 2000; Lagerkvist et al. 2004).
Serum CC16 concentrations are decreased in
individuals with compromised lung condition
Arsenic, CC16, and respiratory effects
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Table 3. Linear regression analyses for the effects of urinary As metabolites on serum CC16 levels among all participants as well as stratified by skin
lesions status.
Log transformed CC16
Model Subjects with skin lesions Subjects without skin lesions
Log-transformed (n = 238) (n = 126) (n = 112)
measure Parameter estimatea p-Value Parameter estimatea p-Value Parameter estimatea p-Value
MMA:InAs –0.08218 0.18 –0.07449 0.47 –0.08224 0.30
DMA:MMA 0.12532 0.05 0.04883 0.62 0.18238 0.04
aAdjusted for age, sex, BMI, and log-transformed water As concentration. 
Table 4. Pearson’s correlation coefficients for the associations between urinary As and its metabolites
and spirometric measures (predictive FEV1 and FVC values) of lung functions (n = 31).
Urinary As MMA:InAs DMA:MMA
Spirometry measures r (p) r (p) r (p)
FEV1 –0.37 (0.03) –0.21 (0.20) 0.30 (0.09)
FVC –0.35 (0.04) –0.05 (0.70) 0.27 (0.14)
FEV1/FVC –0.36 (0.04) –0.42 (0.01) 0.29 (0.10)
Table 5. Serum CC16 concentrations by predictive FEV1 and FVC values (n = 31).
Mean urinary  Mean CC16
Spirometry measures Predictive value Percent (n) As (µg/L) (µg/L) p-Valuea
FEV1 ≤ 70 23 (7) 514.42 3.58 0.05
> 70 77 (24) 329.08 7.71
FVC ≤ 70 26 (8) 460.5 3.50 0.02
> 70 74 (23) 339.78 7.92
aBetween mean differences of CC16 concentration.induced by chronic environmental exposures
such as cigarette smoking or ozone (Bernard
et al. 1994; Berthoin et al. 2004; Lagerkvist
et al. 2004). In such conditions Clara cells are
damaged by inflammation, which results in
decreased production of CC16 and thereby
limiting the ability to repair epithelium dam-
age caused by pollutants (Broeckaert and
Bernard 2000). The mechanism by which
CC16 protects the epithelium is unclear, but
some suggest its role as an antioxidant
(Broeckaert et al. 2000; Broeckaert and
Bernard 2000).
Nonmalignant respiratory effects of As
exposure have been investigated in previous
studies. Six studies from India and Bangladesh
measured prevalence of respiratory symptoms
only in people with visible arsenical skin lesions
who were exposed to As concentrations
> 500 µg/L (De et al. 2004; Mazumder et al.
2000, 2005; Milton et al. 2003; Milton and
Rahman 2002; von Ehrenstein et al. 2005).
Assessment of respiratory illnesses may not
have been completely reliable in these studies.
The study participants had visible skin lesions
and were from highly As-contaminated areas;
this increased chances of interviewer/assess-
ment bias and recall bias. In the present study
we evaluated several indices of As exposure, as
well as As metabolism, in relation to results of
lung function testing and a biomarker of lung
function (CC16). The observation that urinary
As was inversely associated with FEV1, FVC,
and FEV1/FVC ratio in the 31 persons with
no skin lesions conﬁrms the positive associa-
tions between respiratory symptoms and As
exposure observed in populations with very
high concentrations and individuals with skin
lesions (De et al. 2004; Mazumder et al. 2000,
2005; Milton et al. 2003; Milton and Rahman
2002; von Ehrenstein et al. 2005). In the pre-
sent study, study participants were exposed to
an average water As concentration of 134 µg/L
(range, 0.1 µg/L–761 µg/L), much lower than
in previous studies. Our ﬁndings on lung func-
tion and serum CC16 further provide evidence
of lung dysfunction in populations with low to
medium levels of As exposure.
Although we observed an association
between urinary As and serum CC16, we did
not find a strong association with water As
concentration. The difference in association for
the two measures could be due to the fact that
the value of water As, based on a single well,
may not reﬂect the true exposure (if the subject
drinks water from multiple wells). In contrast,
urinary As reﬂects the aggregate exposure from
all sources. Thus urinary As is considered a bet-
ter measure of recent total As exposure.
A limitation of our study is that we did
not collect detailed clinical information on res-
piratory illness and that lung function data
were only available among a subset of study
participants. However, given that the subset
was randomly selected, results on lung func-
tion observed in the subset of the study popu-
lation may also apply to all of the study
participants. It is also unlikely that the
observed association is due to other factors
that may influence serum CC16 concentra-
tions. There has been no evidence that As
exposure from drinking water is related to fac-
tors such as exposure to ozone, occupational
exposure to nitric oxides, or asbestos that may
influence serum concentrations of CC16. In
fact, > 95% of the population in our study
area use biofuels for cooking. Chen et al.
(2007) reported no apparent association
between well As concentration and occupation
or indicators of socioeconomic status (SES)
including educational status and land owner-
ship. The distribution of occupation of the
parent cohort study participants was 53%
homemakers, 10% farmers or agriculture
labors, 18% small business, 10% workers in
textile or dyes, and 10% unemployed. In addi-
tion, controlling for indicators of SES, includ-
ing educational attainment and occupations,
did not change the effect estimates appreciably
(data not shown).
Several studies have shown that smokers
with As exposure are at a higher risk of devel-
oping respiratory illness (Mazumder et al.
2005; von Ehrenstein et al. 2005). Our ﬁnd-
ings further suggest that the effect of As expo-
sure on respiratory illness may be significant
among nonsmokers, because we restricted the
study to only never-smokers. We have also
found that smoking plays an additive role in
As-induced respiratory illnesses (Parvez F,
Chen Y, Joseph HG, Brandt-Rauf PW, Argos
M, Slavkovich V, Islam T, Hassan R, Balac
O, and Ahsan H, unpublished data). Hays
et al. (2006) has reported a synergistic effect
of As and cigarette smoking to increase DNA
oxidation in the lung. 
Presently, invasive procedures for detect-
ing respiratory illnesses, such as bronchoscopy
or bronchoalveolar lavage techniques, are not
suitable for large-scale population studies in
rural Bangladesh. Also, self-reported symp-
toms or lung function tests usually detect dis-
ease with relatively late-stage lung damage. In
contrast, an appropriate biological marker
such as CC16 can be used to detect respiratory
illnesses at an early stage and it is easy to use,
making it especially attractive for tracking res-
piratory damage from As or other exposure in
populations such as in Bangladesh.
In conclusion, we observed an inverse
association of serum CC16 with As exposure
and a positive association with As methylation
capacity in this Bangladeshi population. These
associations differed by participants’ skin
lesion status. We infer that the methylation of
InAs to DMA is protective against respiratory
effects of As, because those with a higher ratio
of DMA/MMA appeared to be at decreased
risk for lung dysfunction. We also observed a
deleterious effect of urinary As on lung func-
tion, as assessed by FEV1 and FVC. These
novel ﬁndings need to be conﬁrmed in future
larger studies.
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